Amalgamated Bank Has $90,000 Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Amalgamated Bank increased its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 22.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,840 shares of the company’s stock after acquiring an additional 530 shares during the quarter. Amalgamated Bank’s holdings in IDEAYA Biosciences were worth $90,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Nisa Investment Advisors LLC lifted its position in shares of IDEAYA Biosciences by 38.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock valued at $117,000 after acquiring an additional 927 shares during the period. Swiss National Bank lifted its position in shares of IDEAYA Biosciences by 30.9% during the 1st quarter. Swiss National Bank now owns 111,400 shares of the company’s stock valued at $4,888,000 after acquiring an additional 26,300 shares during the period. Quest Partners LLC bought a new stake in shares of IDEAYA Biosciences during the 2nd quarter valued at $41,000. Price T Rowe Associates Inc. MD lifted its position in shares of IDEAYA Biosciences by 13.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,052,500 shares of the company’s stock valued at $177,825,000 after acquiring an additional 486,222 shares during the period. Finally, Scientech Research LLC lifted its position in shares of IDEAYA Biosciences by 362.3% during the 2nd quarter. Scientech Research LLC now owns 27,708 shares of the company’s stock valued at $973,000 after acquiring an additional 21,714 shares during the period. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Trading Down 9.6 %

Shares of IDYA opened at $26.64 on Monday. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -11.43 and a beta of 0.86. The stock has a 50 day moving average of $31.42 and a 200 day moving average of $36.30. IDEAYA Biosciences, Inc. has a 12 month low of $26.41 and a 12 month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same period in the previous year, the company earned ($0.46) EPS. As a group, equities research analysts predict that IDEAYA Biosciences, Inc. will post -2.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Oppenheimer reiterated an “outperform” rating and set a $53.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Cantor Fitzgerald initiated coverage on IDEAYA Biosciences in a research report on Tuesday, October 15th. They set an “overweight” rating for the company. Leerink Partners downgraded IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $41.00 to $27.00 in a research report on Tuesday, November 5th. Leerink Partnrs downgraded IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Finally, Wedbush restated an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Monday, November 4th. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.91.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.